Acetaminophen Aspirin Codeine

Name: Acetaminophen Aspirin Codeine

Indications and Usage for Acetaminophen Aspirin Codeine

Acetaminophen, aspirin, and codeine phosphate capsules are indicated for the relief of mild to moderately severe pain.

Contraindications

Acetaminophen, aspirin, and codeine phosphate preparations should not be administered to patients who have previously exhibited hypersensitivity to any component. Aspirin containing products are contraindicated in patients with bleeding disorders.

Precautions

General

Head Injury and Increased Intracranial Pressure: The respiratory depressant effects of narcotics and their capacity to elevate cerebrospinal fluid pressure may be markedly exaggerated in the presence of head injury, other intracranial lesions or a pre-existing increase in intracranial pressure. Furthermore, narcotics produce adverse reactions which may obscure the clinical course of patients with head injuries.

Acute Abdominal Conditions: The administration of this product or other narcotics may obscure the diagnosis or clinical course of patients with acute abdominal conditions.

Special Risk Patients: This drug should be given with caution to certain patients such as the elderly or debilitated, and those with severe impairment of hepatic or renal function, hypothyroidism, Addison’s disease, and prostatic hypertrophy or urethral stricture. Salicylates should be used with caution in patients with gastritis, peptic ulceration or coagulation abnormalities.

Information for Patients

Codeine may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery. The patient using this drug should be cautioned accordingly.

Caution patients with a predisposition for gastrointestinal bleeding that concomitant use of aspirin and alcohol may have an additive effect in this regard.

Drug Interactions

Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with this drug may exhibit an additive CNS depression. When such combined therapy is contemplated, the dose of one or both agents should be reduced.

The concurrent use of anticholinergics with codeine may produce paralytic ileus.

Salicylates may enhance the effect of anticoagulants and inhibit the uricosuric effect of uricosuric agents.

Carcinogenesis, Mutagenesis, Impairment of Fertility

No long-term studies in animals have been performed with acetaminophen or codeine to determine carcinogenic potential or effects on fertility.

Acetaminophen and codeine have been found to have no mutagenic potential using the Ames Salmonella-Microsomal Activation test, the Basc test on Drosophila germ cells, and the Micronucleus test on mouse bone marrow.

Pregnancy

Teratogenic Effects

 Pregnancy Category C

Codeine: A study in rats and rabbits reported no teratogenic effect of codeine administered during the period of organogenesis in doses ranging from 5 to 120 mg/kg. In the rat, doses at the 120 mg/kg level, in the toxic range for the adult animal, were associated with an increase in embryo resorption at the time of implantation. In another study a single 100 mg/kg dose of codeine administered to pregnant mice reportedly resulted in delayed ossification in the offspring.

There are no studies in humans, and the significance of these findings to humans, if any, is not known.

Studies in rodents have shown salicylates to be teratogenic when given in early gestation, and embryocidal when given in later gestation in doses considerably greater than usual therapeutic doses in humans. Studies in women who took aspirin during pregnancy have not demonstrated an increased incidence of congenital abnormalities in the offspring.

This combination product should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nonteratogenic Effects

Dependence has been reported in newborns whose mothers took opiates regularly during pregnancy. Withdrawal signs include irritability, excessive crying, tremors, hyperreflexia, fever, vomiting, and diarrhea. These signs usually appear during the first few days of life.

Labor and Delivery

Narcotic analgesics cross the placental barrier. The closer to delivery and the larger the dose used, the greater the possibility of respiratory depression in the newborn. Narcotic analgesics should be avoided during labor if delivery of a premature infant is anticipated. If the mother has received narcotic analgesics during labor, newborn infants should be observed closely for signs of respiratory depression. Resuscitation may be required (see OVERDOSAGE). The effect of codeine, it any, on the later growth, development, and functional maturation of the child is unknown.

Ingestion of aspirin near term or prior to delivery may prolong delivery or lead to bleeding in mother, fetus or neonate.

Nursing Mothers

Some studies, but not others, have reported detectable amounts of codeine in breast milk. The levels are probably not clinically significant after usual therapeutic dosage. The possibility of clinically important amounts being excreted in breast milk in individuals abusing codeine should be considered.

Aspirin is excreted in human milk in moderate amounts and can produce a bleeding tendency in nursing infants. Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or the drug, taking into account the importance of the drug to the mother.

Adverse Reactions

The most frequently observed adverse reactions include lightheadedness, dizziness, sedation, shortness of breath, nausea and vomiting. These effects seem to be more prominent in ambulatory than in non-ambulatory patients, and some of these adverse reactions may be alleviated if the patient lies down. Other adverse reactions include allergic reactions, euphoria, dysphoria, constipation, abdominal pain and pruritus.

At higher doses codeine has most of the disadvantages of morphine including respiratory depression.

The most common adverse reactions associated with the use of aspirin have been gastrointestinal, including nausea, vomiting, gastritis, occult bleeding, constipation and diarrhea. Gastric erosion, angioedema, asthma, rash, pruritus and urticaria have been reported less commonly. Tinnitus is a sign of high serum salicylate levels (see OVERDOSAGE).

Aspirin Intolerance: Allergic type reactions in aspirin-sensitive individuals may involve the respiratory tract or the skin. Symptoms of the former range from rhinorrhea and shortness of breath to severe asthma, and the latter may consist of urticaria, edema, rash or angioedema (giant hives). These may occur independently or in combination.

How is Acetaminophen Aspirin Codeine Supplied

Acetaminophen, Aspirin, and Codeine Phosphate Capsules, 150 mg/180 mg/15 mg, each capsule of which contains acetaminophen 150 mg, aspirin 180 mg, and codeine phosphate 15 mg (WARNING: May be habit forming), are available as an opaque grey body and opaque green capped capsule, imprinted “LPI/LPI” in black, and are supplied in bottles of 100 capsules, NDC 46672-231-10.

Acetaminophen, Aspirin, and Codeine Phosphate Capsules, 150 mg/180 mg/30 mg, each capsule of which contains acetaminophen 150 mg, aspirin 180 mg, and codeine phosphate 30 mg (WARNING: May be habit forming), are available as an opaque grey body and opaque black capped capsule, imprinted “LPI/LPI” in white, and are supplied in bottles of 100 capsules, NDC 46672-230-10.

Acetaminophen, Aspirin, and Codeine Phosphate Capsules, 150 mg/180 mg/60 mg, each capsule of which contains acetaminophen 150 mg, aspirin 180 mg, and codeine phosphate 60 mg (WARNING: May be habit forming), are available as an opaque grey body and opaque red capped capsule, imprinted “LPI/LPI” in black, and are supplied in bottles of 100 capsules, NDC 46672-236-10.

Storage: Protect from moisture. Store at controlled room temperature 15-30ºC (59-86ºF).

Dispense in a tight, light-resistant container with a child-resistant closure.

CAUTION: Federal law prohibits dispensing without prescription.

Manufactured by:
MIKART, INC.
Atlanta, GA 30318

Rev. 09/91                                   Code 472Z00, 473Z00, 474Z00

ACETAMINOPHEN, ASPIRIN AND CODEINE PHOSPHATE 
acetaminophen, aspirin and codeine phosphate capsule
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:46672-231
Route of Administration ORAL DEA Schedule CIII    
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
ACETAMINOPHEN (ACETAMINOPHEN) ACETAMINOPHEN 150 mg
ASPIRIN (ASPIRIN) ASPIRIN 180 mg
CODEINE PHOSPHATE (CODEINE) CODEINE 15 mg
Inactive Ingredients
Ingredient Name Strength
BLACK IRON DIOXIDE  
D&C YELLOW#10  
FD&C RED #40  
GELATIN  
PREGELATINIZED STARCH  
SILICON DIOXIDE  
SODIUM LAURYL SULFATE  
TITANIUM DIOXIDE  
Product Characteristics
Color GRAY, GREEN Score no score
Shape CAPSULE Size 19mm
Flavor Imprint Code LPI;LPI
Contains     
Coating false Symbol false
Packaging
# Item Code Package Description
1 NDC:46672-231-10 100 CAPSULE (100 CAPSULE) in 1 BOTTLE
ACETAMINOPHEN, ASPIRIN AND CODEINE PHOSPHATE 
acetaminophen, aspirin and codeine phosphate capsule
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:46672-230
Route of Administration ORAL DEA Schedule CIII    
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
ACETAMINOPHEN (ACETAMINOPHEN) ACETAMINOPHEN 150 mg
ASPIRIN (ASPIRIN) ASPIRIN 180 mg
CODEINE PHOSPHATE (CODEINE) CODEINE 30 mg
Inactive Ingredients
Ingredient Name Strength
BLACK IRON DIOXIDE  
GELATIN  
PREGELATINIZED STARCH  
SILICON DIOXIDE  
SODIUM LAURYL SULFATE  
TITANIUM DIOXIDE  
Product Characteristics
Color GRAY, BLACK Score no score
Shape CAPSULE Size 19mm
Flavor Imprint Code LPI;LPI
Contains     
Coating false Symbol false
Packaging
# Item Code Package Description
1 NDC:46672-230-10 100 CAPSULE (100 CAPSULE) in 1 BOTTLE
ACETAMINOPHEN, ASPIRIN AND CODEINE PHOSPHATE 
acetaminophen, aspirin and codeine phosphate capsule
Product Information
Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:46672-236
Route of Administration ORAL DEA Schedule CIII    
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
ACETAMINOPHEN (ACETAMINOPHEN) ACETAMINOPHEN 150 mg
ASPIRIN (ASPIRIN) ASPIRIN 180 mg
CODEINE PHOSPHATE (CODEINE) CODEINE 60 mg
Inactive Ingredients
Ingredient Name Strength
BLACK IRON DIOXIDE  
FD&C BLUE #1  
FD&C RED #40  
GELATIN  
PREGELATINIZED STARCH  
SILICON DIOXIDE  
SODIUM LAURYL SULFATE  
TITANIUM DIOXIDE  
Product Characteristics
Color GRAY, RED Score no score
Shape CAPSULE Size 22mm
Flavor Imprint Code LPI;LPI
Contains     
Coating false Symbol false
Packaging
# Item Code Package Description
1 NDC:46672-236-10 100 CAPSULE (100 CAPSULE) in 1 BOTTLE
Revised: 12/2006  
(web3)